Τόμος 10 (1996) – Τεύχος 2 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 10 (1996) – Issue 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

The Stehlin Foundation for Cancer Research at St. Joseph Hospital, Houston, Texas 77003, USA

Accepted for publication: 20 June 1996

pharmakonpress[at]pharmakonpress[.]gr

2.    Kessel, D.: Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochem. Biophys. Acta 246: 225 (1971)

3.    Horwitz, S.B., Chang, C-Κ., Groltman, A.P.: Studies on camptothecin. 1. Effects on nucleic acid and protein synthesis. Mol. Pharmacol. 7: 632 (1971)

4.    Wu, R.S., Kumar, A., Warner, J.R.: Ribosomal formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis. Proc. Natl. Acad. Sci. USA 68: 3009 (1971)

5.    Kessel, D., Bosmann, H.B., Lohr, K.: Camptothecin effects on DNA synthesis of murine leukemia cells. Biochim. Biophys. Acta. 269: 210 (1972)

6.    Abelson, H.T., Penman, S.: Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin. Nature New Biot. 237: 144 (1972)

7.    Bendixen, C., Thomsen, B., Alsner, J., Westergaard, O.: Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 12: 5613 (1990)

8.    Muggia, F.M. Twenty years later: Review of clinical trials with camptothecin sodium (NSC 100880). In: (Potmesil, M., Pinedo, H., eds) Camptothecins: New Anticancer Agents, p. 43. Boca Raton, CRC Press, 1995

9.    Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W., Liu, L.F., Siiber, R., Potmesil, M.: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046 (1989)

10.  Giovanella, B.C., Hinz, H.R., Kozielski, A.J., Stehlin, J.S., Siiber, R., Potmesil, M.: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res. 51: 3052 (1991)

11.  Pantazis, P., Hinz, H.R., Mendoza, J.T., Kozielski, A.J., Williams, L.J., Stehlin, J.S., Giovanella, B.C.: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice by camptothecins. Cancer Res. 52: 3980 (1992)

12.  Pantazis, P., Mendoza, J.T., Kozielski, A.J., Natelson, E.A., Giovanella, B.C.: 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur. J. Haematol. 50: 81 (1993)

13.  Pantazis, P., Early, J.A., Kozielski, A.J., Mendoza, J.T., Hinz, H.R., Giovanella, B.C.: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9- nitro-camptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res. 53: 1577 (1993)

14.  Pantazis, P., Kozielski, A.J., Mendoza, J.T., Early, J.A., Hinz, H.R., Giovanella, B.C.: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53: 863 (1993)

15.  Pantazis, P., Early, J.A., Mendoza, J.T., DeJesus, A.R., Giovanella, B.C.: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. 54: 771 (1994)

16.  Pantazis, P., Kozielski, A.J., Vardeman, D.M., Petry, E.R., Giovanella, B.C.: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncology Res. 5: 273 (1993)

17.  Jaxel, C., Kohn, K.W., Want, M.C., Wall, M.E., Pommier, Y.: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49: 1465 (1989)

18.  Hsiang, Y.-H., Liu, L.F., Wall, M.E., Wani, M.C., Kirshenbaum, S., Silber, R., Potmesil, M.: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 49: 4385 (1989)

19.  Wall, M.E., Wani, M.C.: Antineoplastic agents from plants. Ann. Rev. Pharmacol. Toxicol. 17: 117 (1977)

20.  Burke, T.G., Mi, Z.: Preferential binding of the carboxylate form of camptothecin by human serum albumin. Analyt Biochem. 212: 285 (1993)

21.  Wall, M.E., Wani, M.C.: Chemistry and antitumor activities of camptothecins. In: (Potmesil, M., Kohn, K.W., eds.) DNA Topoisomerases in Cancer, p. 93, New York, Oxford University Press, 1991

22.  Mi, Z., Burke, T.G.: Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33: 10325 (1994)

23.  Burke, T.G., Munshi, C.B., Mi, Z., Jiang, Y.: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci. 84: 518 (1995)

24.  Eckardt, J.R., Burris, H.A., Rothenberg, M.L., Von Hoff, D.D., Kuhn, J.G.: Topoisomerase I inhibitors: Promising novel compounds. Contemporary Oncology, Jan.: 47 (1993)

25.  Creemers, G.J., Lund, B., Verweij, J.: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat. Rev. 29: 73 (1994)

26.  Bowen, K., Fields, S., Buris, H.: Topoisomerase I inhibitors: A new class of anticancer agents. Adv. Oncology 19: 16 (1994)

27.  Potmesil, M.: Camptothecins: From bench research to hospital wards. Cancer Res. 54: 1431 (1994)

28.  Tanizawa, A., Fujimori, A., Fujimori, Y., Pommier, Y.: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 86: 836 (1994)

29.  Stehlin, J.S., Natelson, E.A., Hinz, H.R., Giovanella, B.C., de Ipolyi, P.D., Fehir, K.M., Trezona, T.P., Vardeman, D.M., Harris, N.J., Marcee, A.K., Kozielski, A.J., Ruiz- Razura, A.: Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)-camptothecin. In: (Potmesil, M., Pinedo, H., eds) Camptothecins: New Anticancer Agents, p. 59, CRC Press, Boca Raton, FL, 1995

30.  Muggia, F.M., Burris, H.A.: Clinical development of topoisomerase-interactive drugs. Adv. Pharmacol. 29A: 1 (1995)

31.  Potmesil, M., Pinedo, H. (eds.): Camptothecins: New Anticancer Drugs. Boca Raton, FL, CRC Press, 1995

32.  Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer, D., Kufe, D.: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. 1: 269 (1995)

33.  Giovanella, B.: Topoisomerase I inhibitors. In: (Teicher, B. ed.) Cancer Drug Discovery. Academic Press, New York, 1996

34.  Hsiang, Y.-H., Hertzberg, R., Hecht, S, Liu, L.F.: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 269: 14873 (1985)

35.  Caron P., Wang J. C.: DNA topoisomerases as targets of therapeutics: A structural overview. In: (Ando, T., Ikeda, N., Oguro, M., eds.) Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy, p. 1, Boca Raton, FL: CRC Press, 1993

36.  T. Andoh, H. Ikeda, M. Oguro (eds): Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy, Boca Raton, FL: CRC Press, 1993

37.  L.F, Liu (ed.): DNA Topoisomerases: Biochemistry and Molecular Biology, Adv. Pharmacol., vol. 29A, 1994

38.  Hsiang, Y.-H., Liu, L.F.: Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722 (1988)

39.  Hertzberg, R., Caranfa, M., Hecht, S.; On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to a enzyme-DNA complex. Biochemistry 28: 4629 (1989)

40.  Pommier, Y., Jaxel, C., Heise, C.R., Kerrigan, D., Kohn, K.W.: Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: (Potmesil, M., Kohn, K.W., eds) DNA Topoisomerases in Cancer, p.121, New York, Oxford University Press, 1991

41.  Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K., Pommier, Y.: Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 226: 20418 (1991)

42.  Porter, S.E., Ohampoux, J.J.: The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res. 17: 8521 (1989)

43.  Champoux, J.J.: DNA is linked to the rat liver nicking- dosing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem. 256: 4805 (1981)

44.  Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K.W., Pommier, Y.: Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 2: 8955 (1994)

45.  Zhang, H., D’Arpa, P., Liu, L.: A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2: 23 (1990)

46.  Hsiang, Y.-H., Lihou, M.G., Liu, L.F.: Arrest of replication forks by drug-stabilized topoisomerase l-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49: 5077 (1989)

47.  Tsao, Y-P., Russo, A., Nyamuswa, G., Silber, R., Liu, L.F.: Interaction between replication forks and topoisomerase 1-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system. Cancer Res. 53: 5908 (1993)

48.  Yoshida, A., Ueda, T., Wano, Y., Nakamura, T.: DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn. J. Cancer Res. 84: 566 (1993)

49.  Gallo, R.C., Whang-Peng, J., Adamson, R.H.: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 48: 789 (1971)

50.  Del Bino, G., Skierski, J.S., Darzynkiewicz, Z.: Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG-1) leukemia cells. Cancer Res. 50: 5746 (1990)

51.  D’Arpa, P., Beardmore, C., Liu, L.F.: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 58: 6919 (1990)

52.  Del Bino, G., Darzynkiewicz, Z.: Camptothecin, teniposide, or 4′-(9-acridinyl-amino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res. 51: 1165 (1991)

53.  Kharbanda, S., Rubin, E., Gunji, H., Hinz, H., Giovanella, B., Pantazis, P., Kufe, D.: Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res. 51: 6636 (1991)

54.  Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.A., Lassota, P., Traganos, F.: Features of apoptotic cells by flow cytometry. Cytometry 13: 795 (1992)

55.  Lanza, A., Tornaletti, S., Stefanini, M., Evans, H.H., Ricanati, M., Astaldi-Ricotti, J., Pedrini, A.M.: The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Carcinogenesis 14: 1759 (1993)

56.  Ryan, A.J., Squires, S., Strutt, H.L., Evans, A., Johnson, R.T.: Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis 15: 823 (1994)

57.  Kohn, K.W., Jackman, J., O’Connor, P.M.: Cell cycle control and cancer chemotherapy. J. Cell. Biochem. 54: 440 (1994)

58.  Smith, P.J., Makinson, T.A., Watson, J.V.: Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol. 55: 217 (1989)

59.  Squires, S., Ryan, A.J., Strutt, H.L., Johnson, R.T.: Hypersensitivity of Cockayne’s syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 53: 2012 (1993)

60.  Goldwasser, F., Bae, l., Valenti, M., Torres, K., Pommier, Y.: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer Screen. Cancer Res. 55: 2116 (1995)

61.  Chatterjee, S., Cheng, M.F., Berger, N.A.: Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2: 401 (1990)

62.  Tsao, Y.P., D’Arpa, P., Liu L.F.: The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34^cdc2/cyclin B. Cancer Res. 52: 1823 (1992)

63.  Shimizu, T., O’Connor, P.M., Kohn, K.W., Pommier, Y.: Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 55: 228 (1995)

64.  Gong, J., Ardelt, B., Traganos, F., Darzynkiewicz, Z.: Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res. 54: 4285 (1994)

65.  Houghton, J.A., Harwood, F.G., Houghton, P.J.: Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res. 54: 496 (1994)

66.  Khaoustov, V.I., Ozer, A., Smith, J.R., Noda, A., Mearns, M., Krishnan, B., Slagle, B.L., Yoffe, B.: Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDH, in heptoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin. Lab. Invest. 73: 118 (1995)

67.  Pandey, S., Wang, E.: Cells en route to apoptosis are characterized by the upregulation of c-fos, 6-myc, c-jun, cddZ and RB phosphorylation, resembling events of early cell-cycle traverse. J. Celt. Biochem. 58: 135 (1995)

68.  Wani, M.C., Nicholas, A.W., Wail, M.E.: Plant antitumor agents 23. Synthesis and antileukemia activity of camptothecin analogs. J. Med. Chem. 28: 2358 (1986)

69.  Wall, M.E., Wani, M.C.: Antineoplastic agents from plants. Ann. Rev. Pharmacol. Toxicol. 17: 117 (1977)

70.  Pantazis, P., Kozielskr, A., Rodriguez, R., Petry, E., Wall, M., Giovanella, B.C.: Therapeutic efficacy of camptothecin-derivatives against human malignant melanoma xenografts. Melanoma Res. 4: 5 (1994)

71.  Hinz, H.R., Harris, N.J., Natelson, E.A., Giovanella, B.C.: Pharmacokinetics of the in vivo and in vitro conversion of 9- nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in human, dog and mouse. Cancer Res. 54: 3096 (1994)

72.  Pantazis, P., Harris, N., Mendoza, J., Giovanella, B.: Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur. J. Haematol. 53: 246 (1994)

73.  Pantazis, P., Harris, N., Mendoza, J., Giovanella, B.: The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecrn by human hematopoietic and other cells. Eur. J. Haematol. 55: 211 (1995)

74.  Nakaya, K., Chou, S., Kaneko, M., Nakamura, Y.: Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn. J. Cancer Res. 82: 184 (1991)

75.  Chou, S., Kaneko, M., Nakayha, K., Nakamura, Y.: Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem. Biophys. Res. Commun. 1656: 160 (1990)

76.  McSheehy, P.M.J., Gervasoni, M., Lampasona, V., Erba, E., D’lncalci, M.: Studies of the differentiation properties of camptothecin in the human leukaemic cells K562. Eur. J. Cancer 27: 1406 (1991)

77.  Aller, P., Rius, C., Mata, F., Zorilla, A., Cabanas, C., Bellon, T., Bernabeu, C.: Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res. 52: 1245 (1992)

78.  Mitchell, P.I., Tjian, R.: Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 245: 371 (1989)

79.  Zhang, H., Wang, J.C., Liu, L.F.: Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA. 85: 1060 (1988)

80.  Merino, A., Madden, K.R., Lane, W. S., Champoux, J.J., Reinberg, D.: DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365: 227 (1993)

81.  Schonfeld, S., Schulz, S., Nyce, J.W.: Effects of inhibitors of topoisomerases I and II on DNA methylation and DNA synthesis in human colonic adenocarcinoma cells in vitro. Int. J. Oncol. 1: 807 (1992)

82.  Naveh-Many, T., Cedar, H.: Active gene sequences are undermethylated. Proc. Natl. Acad. Set. USA 78: 4246 (1981)

83.  Riggs, A.D., Jones, P.A.: 5-Methylcytosine, gene regulation and cancer. Adv. Cancer Res. 40: 1 (1983)

84.  Gieseler, F., Boege, F., Clark, M., Mayer, P.: Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoietic cell differentiation. Toxicol. Lett. 67: 331 (1993)

85.  Kaufmann, S.H.: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 51: 1129 (1991)

86.  Bertrand, R., O’Connor, P.M., Kerrigan, D., Pommier, Y.: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer 28A: 743 (1992)

87.  Taudou, G., Portemer, C., Jaxel, C., Duguet, M.: Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons. Biochem. Pharmacol. 45: 331 (1993)

88.  Pantazis, P., Mendoza, J.T., DeJesus, A., Rubin, E., Kufe, D., Giovanella B.C.: Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitro-camptothe-cin. Eur. J. Haematol. 58: 135 (1994)

89.  Pantazis, P., Mendoza, J., DeJesus, A., Early, J., Shaw, M., Giovanella, B.: Development of resistance to 9-nitro- camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anti-Cancer Drugs 5: 473 (1994)

90.  Pantazis, P., Vardeman, D., Mendoza, J., Early, J., Kozielski, A., DeJesus, A., Giovanella, B.: Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leukemia Res. 19: 45 (1995)

91.  Pantazis, P., Chatterjee, D., Wyche, J., DeJesus, A., Giovanella, B.: Functional and physiological alterations in human U-937 leukemia cells resistant to etoposide (in preparation)

92.  Beck, W.T.: Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance. J. Natl. Cancer Inst. 81: 1683 (1989)

93.  Tan, K.B., Mattern, M.R., Eng, W.-K., McCabe, F.L., Johnson, R.K.: Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81: 1732 (1989)

94.  Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L.F., Tsuruo, T.: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 50: 7962 (1990)

95.  Pantazis, P., DeJesus, A., Early, J., Rodriguez, R., Giovanella, B.: Development of human leukemia U937 cell sublines resistant to doxorubicin: Induction of differentiation and topoisomerase-directed drugs. Anticancer Res. 15: 1873 (1995)

96.  Pantazis, P., Chatterjee, D., Han, Z., Wyche, J., DeJesus, A., Giovanella, B.: Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U-937 cells acquiring resistance to Vincristine. Eur. J. Haematol: 1996 (in press)

97.  Bradley, G., Naik, M., Ling, V.: P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 49: 2790 (1989)

98.  Kirschner, L.S., Greenberger, L.M., Hsu, Sl-H., Yang, C-PH., Cohen, D., Piekarz, R.L., Castillo, G., Han, EK-H., Yu, L. and Horwitz, S.B.: Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells. Biochem. Pharmacol. 43: 77 (1992)

99.  Fairchild, C.R., Ivy, S.P., Kao-Shan, C.-S., Whang-Peng, J., Rosen, N., Israel, M.A., Melera, P.W., Cowan, K.H., Goldsmith, M.E.: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 47: 5141 (1987)

100. Ganapathi, R., Grabowski, D., Ford, J., Heiss, C., Kerrigan, D., Pommier, Y.: Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: Reductions in drug-induced topoisomersase II- mediated DNA cleavage. Cancer Comm. 1: 217 (1989)

101. Pratt, W.B., Ruddon, R.W., Ensminger, W.D., Maybaum, J. (eds): The Anticancer Drugs, 2^nd ed., Chapter 4: Resistance to anticancer drugs, p. 50. New York, Oxford University Press, 1994

102. Gerlach, J.H., Kartner, N., Bell, D.R., Ling, V.: Multidrug resistance. Cancer Surv. 5: 25 (1986)

103. Endicott, J.A., Ling, V.: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58: 137 (1989)

104. Cole, S.P.C., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Dunkan, A.M.V., Deeley, R.G.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650 (1992)

105. Schneider, E,, Horton, J.K., Yang, C-H., Nakagawa, M., Cowan, K.H.: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54: 152 (1994)

106. Grant, C.E., Valdimarsson, G., Hipfner, D.R., Amquist, K.C., Cole, S.P.C., Deeley, R.G.: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54: 357 (1994)

107. Kruh, G.D., Chan, A., Myers, K„ Gaughan, K., Miki, T., Aaronson, S.A.: Expression of complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 54: 1649 (1994)

108. Slapak, C.A., Mizunuma, N., Kufe, D.W.: Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 84: 3113 (1994)

109. Slapak, C.A., Fracasso, P.M., Martell, R.L., Topp- meyer, D.L., Lecerf, J.-M., Levy, S.B.: Overexpression of the multidrug resistance-associated protein gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res. 54: 5607 (1994)

110. Zaman, G.J.R., Versantovoort, C.H.M., Smit, J.J.M., Eijdems, E.W.H.M., de Haas, M., Smith, A.J., Broxterman, H.J., Mulder, N.H., de Vries, E.G.E., Baas, F., Borst, P.: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53: 1747 (1993)

111. Chen, A.Y., Potmesil, M., Wall, M.E., Want, M.C., Liu, L.F.: Camptothecin overcomes MDRI-mediated resistance in human KB carcinoma cells. Cancer Res. 51: 6039 (1991)

112. Rubin, E., Pantazis, P., Bharti, T., Toppmeyer, D., Giovanella, B.C., Kufe, D.: Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem. 269: 2433 (1994)

113. Nakaya, K., Chou, S., Kaneko, M., Nakamura, Y.: Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn. J. Cancer Res. 82: 184 (1991)

114. Rosenberg, B.H., Ungers, G., Deutsch, J.F.: Variation in DNA swivel enzyme activity during the mammafian cell cycle. Nucleic Acids Res. 3: 3305 (1976)

115. Poccia, D.L., LeVine, D., Wang, J.C.: Activity of a DNA topoisomerase (nicking-closing enzyme) during sea urchin development and the cell cycle. Dev. Biol. 64: 273 (1978)

116. Tricoli, J.V., Sahai, B.M., McCormick, P.J., Jarlinski, S.J., Bertram, J.S., Kowalski, D.: DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells. Expl. Cell Res. 158: 1 (1985)

117. Heck, M.M.S., Earnshaw, W.C.: Topoisomerase II: A specific marker for cell proliferation. J. Cell. Biol. 103: 2569 (1986)

118. Hsiang, Y-H., Wu, H.Y., Liu, L.F.: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48: 3230 (1988)

119. Heck, M.S., Hittelman, W.N., Earnshaw, W.C.: Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA 85: 1086 (1988)

120. Tse-Dinhm, Y.C., Wong, T.W., Goldberg, A.R.: Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerase in vitro. Nature 312: 785 (1984)

121. Kaiserman, H.B., Ingebritsen, T.S., Benbow, R.M.: Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro. Biochem. 27: 3216 (1988)

122. Samuels, D.S., Shimizu, Y., Shimizu, N.: Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett. 259: 57 (1989)

123. Coderoni, S., Paparelli, M., Gianfranceschi, G.L.: Role of calf thymus DNA-topoisomerase l phosphorylation on relaxation activity expression and on DNA-protein interaction. Role of DNA-topoisomerase I phosphorylation. Mol. Biol, Rep. 14: 35 (1990)

124. Samuels, D.S., Shimizu, N.: DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-0-tetradecanoylphorbol-13-acetate and in vitro by protein kinase C. J. Biol. Chem. 267: 11156 (1992)

125. Pommier, Y., Kerrigan, D., Hartman, K.D., Glazer, R.I.: Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J. Biol. Chem. 265: 9418 (1990)

126. Cardellini, E., Durban, E.: Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12-myristate 13-acetate-activated HL-60 promyelocytic leukemia cells. Biochem, J. 291: 303 (1993)

127. Tanizawa, A., Pommier, Y.: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 52: 1848 (1992)

128. Baloch, Z., Cohen, S., Coffman, P.D.: Synergistic inter-actions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J. Immunol. 145: 2908 (1990)

129. Utsugi, T., Mattern, M.-R., Mirabelli, C.K., Hanna, N.; Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: Enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res. 50: 2636 (1990)

130. Orengo, G., Noviello, E., Cimoli, G., Pagnan, G., Parodi, S., Venturini, M., Conte, P„ Schenone, F., Conzi, G., Russo, P.: Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: Relationship to DNA strand breakage formation. Jpn. J. Cancer Res. 88: 1132 (1992)

131. Valenti, M., Cimoli, G., Mariani, G.L., Conte, P.F., Parodi, S., Russo, P.: Potentiation of TNF-mediated cell killing by mitoxantrope. Relationship to DNA single-strand break formation. Biochem. Pharmacol. 46: 1199 (1993)

132. Cimoli, G., Valenti, M., Parodi, S., DeSessa, F., Russo, P.: Circumvention of atypical multidrug resistance with tumor necrosis factor. Jpn. J. Cancer Res. 85: 135 (1994)

133. Dealtry, G.B., Naylor, M. S., Fiers, W., Balkwill, F.R.: DNA fragmentation and cytotoxicity caused by tumor necrosis factor. Eur. J. Immunol. 17: 689 (1987)

134. Schmid, D.S., Hornung, R., McGrath, K.M., Paul, N., Ruddle, N.H.: Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymphokine Res. 6: 195 (1987)

135. Rubin, B.Y., Smith, L.J., Hellermann, G.R., Lunn, R.M., Richardson, N.K. and Anderson, S.L.: Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res. 48: 6006 (1988)

136. Spriggs, D.R., Deutsch, S., Kufe, D.W.: Genomic structure, induction, and production of TNF-a. In: (Aggarwal, B.B., Vilcek, J., eds) Tumor Necrosis Factors: Structure, Function, and Mechanism of Action, p. 3 New York, Marcel Dekker, Inc., 1992

137. Elias, L., Berry, C.O.: Induction of differentiation by tumour necrosis factor in HL-60 cells is associated with the formation of large DNA fragments. Leukemia 5: 879 (1991)

138. Greenblatt, M.S., Elias, L,: The type B receptor for tumor necrosis factor-a mediates DNA fragmentation in HL-60 and U-937 cells and differentiation in HL-60 cells. Blood 89P 1339 (1992)

139. Wang, Z., Sinha, B.K.: Interleukin-1a-induced modulation of topoisomerase I activity and DNA damage: Implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Mol. Pharmacol. 49: 269 (1996)

140. Raz, A., Wyche, A., Needleman, P.: Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc. Natl. Acad. Sci. USA 86: 1657 (1989)

141. Bertrand, R., Solary, E., Jenkins, J., Pommier, Y.: Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exptl. Cell. Res. 208: 388 (1993)

142. Abe, K., Yoshida, M., Usui, T., Horinouchi, S., Beppu, T.: Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exptl, Cell. Res. 192: 122 (1991)

143. Crissman, H.A., Gadbois, D.M., Tobey, R.A., Bradbury, E.M.; Transformed mammalian cells are deficient in kinase- mediated control of progression through the G1 phase of the cell cycle. Proc. Natl. Acad. Sc. USA 88: 7580 (1991)

144. Bruno, S., Ardelt, B., Kierski, J.S., Traganos, F., Darzynkiewicz, Z.: Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res. 52: 470 (1992)

145. Crompton, N.E.A., Hain, J., Faussi, R., Burkart, W.: Staurosporine- and radiation-induced G2-phase cell cycle blocks are equally released by caffeine. Radiai Res. 13: 372 (1993)

146. Schnter, J.B., Gadbois, D.M., Nishi, K., Bradbury, E.M.: The kinase inhibitor staurosporine induces Gt arrest at two, points: Effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res. 54: 5959 (1994)

147. Jing, Y., Hashimoto, S., Nakajo, S., Nakaya, K.: Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells. Leukemia Res. 18: 229 (1994)

148. Imaizumi, M., Breitman, T.R.: Retinoic acid-induced differentiation of the human promyelocytic leukemia cell line, HL-60, and fresh human leukemia cells in primary culture: A model for differentiation inducing therapy of leukemia. Eur. J. Haematol. 38: 289 (1987)

149. Warreil, R.P., Frankel, S.R., Miller, W.H.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans-retinoic acid). N. Engl. J. Med. 324: 1385 (1991)

150. Goldwasser, F., Valenti, M., Torres, R., Kohn, K.W., Pommier, Y.: Potentiation of cisplatin cytotoxicity by 9-ami- nocamptothecin. Clin. Cancer Res. 2: 687 (1996)

151. Ghetie, M-A,, Tucker, K, Richardson, J., Uhr, J.W., Vitetta, E.S.: Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84: 702 (1994)

152. Musk, S.R.R., Steel, G.G.: The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase I. Br. J. Cancer 62: 364 (1990)

153. Boothman, D.A., Wang, M., Schea, R.A., Burrows, N.L., Strickfaden, S., Owens, J.K.: Posttreatment exposure to camptothecin unbalances the lethal effects of x-rays on radioresistant malignant melanoma cells. Int. J. Rad. Oncol. Biol. Phys. 24: 939 (1992)

154. Boscia, R.E., Korbut, T., Holden, S.A., Ara, G., Teicher, B.A.: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer 53: 118 (1993)

155. Falk, S.J., Smith, P.J.: DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol. 61: 749 (1992)

156. Del Bino, G., Bruno, S., Yi, P.N., Darzynkiewicz, Z.: Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell. Prolif. 25: 537 (1992)

157. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., Darzynkiewicz, Z.: The cell cycle related differences in susceptibility of HL-60 cells. Cancer Res. 53: 3186 (1993)

158. Hennequin, C., Giocanti, N., Balosso, J., Favaudon, Y.: Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54: 1720 (1994)

159. Boothman, D. A., Fukunaga, N., Wang, M.: Down- regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res. 54: 4618 (1994)

160. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogel- stein, B., Craig, R.W.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304 (1991)

161. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.W., Kastan, M.D.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491 (1992)

162. O’Connor, P.M., Kohn, K.W.: A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin. Cancer Biol. 3: 409 (1992)

163. O’Connor, P.M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., Kohn, K.W.: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt’s lymphoma cell lines. Cancer Res. 53: 4776 (1993)

164. Lee, J.M., Bernstein, A.: p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90: 5742 (1993)

165. Mcllwrath, A.J., Vasey, P.A., Ross, G.M., Brown, R.: Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res. 54: 3718 (1994)

166. Lambert, R.A.:    Demonstration of the greater susceptibility to heat of sarcoma cells. J. Am. Med. Ass. 59: 2147 (1912)

167. Gerner, E.W., Cetas, T.C. (eds): Hyperthermic Oncology 1992, vol. 2, Proceedings of the 6th International Congress on Hyperthermic Oncology, Tucson, Arizona, 1993

168. Giovanella, B.C., Stehlin, J.S., Yim, S.O.: Correlation of the thermosensitivity of cells to their malignant potential. Ann. N.Y. Acad. Sci. 335: 206 (1980)

169. Hahn, G.M.: Thermal enhancement of the actions of anticancer agents. In: (Hahn, G.M., ed.) Hyperthermia and Cancer, p. 55, Plenum Publishing Corp., New York, 1982

170. Fisher, G.A., Hahn, G.M.: Enhancement of cis-platinum(II) diamminedichloride cytotoxicity by hyperthermia. Natl. Cancer Inst. Mongr. 61: 255 (1982)

171. Watanabe, N., Niitsu, Y., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M., Urushizaki, l.: Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 48: 650 (1988)

172. Niitsu, Y., Watanabe, N.. Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M. and Urushizaki, I.: Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res. 48: 654 (1988)

173. Tomasovic, S.P., Barta, M., Klostergaard, J.: Neutral red uptake and clonogenic survival assays of the hyperthermia sensitization of tumor cells to tumor necrosis factor. Rad. Res. 119: 325 (1989)

174. Fujimoto, S., Konno, O., Kobayashi, K., Kokubun, M., Shrestha, R.D., Kiuchi, S., Takahashi, M., Ohta, M., Okui, K.: Augmented antitumor effects of combined treatment with hyperthermia and tumor necrosis factor on human gastric cancer xenotransplanted into nude mice. Int. J. Hyperthermia 7: 511 (1991)

175. Cohen, J.D., Robins, H.I., Schmitt, C.L.: Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide. Cancer Lett. 44: 205 (1989)

176. Kampinga, H.H., Kruk, G.V.D., Konings, A.W.T.: Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4′-(9′-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Cancer Res. 42: 1712 (1989)

177. Dynlacht, J.R., Wong, R.S.L., Albright, N.. Dewey, W.C.: Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Res. 54: 4129 (1994)

178. Teicher, B.A., Holden, S.A., Khandakar, V., Herman, T.S.: Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diaminedichloro-platinum(II)/heat/radiation) in a murine tumor. J. Cancer Res. Clin. Oncol. 119: 645 (1993)

179. Horwitz, M.S.: Adenoviridae and their replication. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, pp.167-172, Raven Press, New York, 1990

180. Kessel, D., Bosmann, H.B., Lohr, K.:. Camptothecin effects on DNA synthesis of murine leukemia cells. Biochlm. Biophys. Acta. 269: 210 (1972)

181. Wong, M.-L., Hsu, M.T.: Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome. J. Virol. 64: 691 (1990)

182. Schaak, J., Schedl, P., Shenk, T.: Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function. Nucleic Acids Res. 18: 1499(1990)

183. Nagata, K., Guggenheimer, R.A., Hurwitz, J.: Adenovirus DNA replication in vitro: Synthesis of full-length DNA with purified proteins. Proc. Natl. Acad. Sci. USA 80: 4266 (1983)

184. Eckhart, W.: Polyomaviridae and their replication. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p. 1593, Raven Press, New York, 1990

185. Shah, K.W.: Polyomaviruses. in: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p. 1609, Raven Press, New York, 1990

186. Wobbe, C.R., Dean, F., Weissbach, L., Hurwitz, J: In vitro replication of duplex circular DNA containing the simian virus 40 DNA origin site. Proc. Natl. Acad. Sci. USA 82: 5710 (1985)

187. Tsao, Y.-P., Russo, A., Nyamuswa, G., Silber, R., Liu, L.F.: Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system. Cancer Res. 53: 5908 (1993)

188. Ishimi, Y., Nishizawa, M,, Ando, T.: Characterization of a camptothecin-resistant human DNA topoisomerase I in an in vitro system for simian virus 40 DNA replication. Eur. J. Biochem. 202: 835 (1991)

189. Snapka, R.M.: Topoisomerase inhibitors can selectively interfere with different stages of simian virus DNA replication. Mol. Cell. Biol. 6: 4221 (1986)

190. Avemann, K., Knippers, R., Koller, T., Sogo, J.M.: Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mot. Cell. Biol. 8: 3026 (1988)

191. Champoux, J.J.: Topoisomerase I is preferentially associated with isolated replicating simian virus 40 molecules after treatment of infected cells with camptothecin. J. Virol 62: 3675 (1988)

192. Shin, C.G., Snapka, R.M.: Exposure of camptothecin breaks leading and lagging strand simian virus 40 DNA replication forks. Biochem. Biophys. Res. Commun. 168: 135 (1990)

193. Padgett, B.J., Walker, D.L., Zu Rhein, M., Eckroade, R.J., Dessel, B.H.: Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1: 1257 (1971)

194. Brook, B.R., Walker, D.L.: Progressive multifocal leukoencephalopathy. Neurol. Clin. 2: 299 (1984)

195. Krupp, L.B., Lrpton, R.B., Swerdlow, M. L., Leeds, N.E., Llena, J.; Progressive multifocal leukoencephalopathy: Clinical and radiographic features. Ann. Neurol 17: 344 (1985)

196. Richardson, E.P.: Progressive multifocal leukoencephalopathy 30 years later. N. Eng. J. Med. 318: 315 (1988)

197. Kerr, D.A., Chang, C.-F., Gordon, J., Bjornsti, M.-A., Khalili, K.: Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virol 196: 612 (1993)

198. Mann, K.: Topoisomerase activity is associated with purified 5V40 T antigen. Nucleic Acids Res. 21: 1697 (1993)

199. Marton, A., Jean, D., Delbecchi, L., Simmons, D.T., Bourgaux, P.: Topoisomerase activity associated with SV40 large tumor antigen. Nucleic Acids Res. 21: 1689 (1993)

200. Marton, A., Marko, B., Delbecchi, L., Bourgaux, P.: Topoisomerase activity associated with polyoma virus large tumor antigen. Biochim. Biophys. Acta 1262: 59 (1995)

201. Kieff, E., Liebowitz, D.: Oncogenesis by Herpesviruses. In: (Weinberg, R.A., ed.) Oncogenes and the Molecular Origins of Cancer, p.259. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989

202. Roizman, B. and Sears, A.E.: Herpes simplex viruses and their replication. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L, Monath. T.P:, Roizman, B., eds) Virotogy, vol. 2, p. 1795. Raven Press, New York, 1990

203. Whitley, R.J.: Herpes simplex viruses, in : (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, Bv eds) Virology, vol. 2, p. 1843, Raven Press, New York, 1990

204. Yamada, Y., Yamamoto, N., Maeno, K., Nishiyamam, Y.: Role of DNA topoisomerase I in the replication of herpes simplex virus type 2. Arch. Virol 118: 121 (1990)

205. Kieff, E., Liebowitz, D.: Epstein-Barr virus and its replication. in: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p.1889, Raven Press, New York, 1990

206. Miller, G.: Epstein-Barr virus: Biology, Pathogenesis, and Medical Aspects. In: (Helds, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p. 1921, Raven Press, New York, 1990

207. Pallesen, G., Hamilton-Dutoid, S.J., Zhou, X.: The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin’s disease: Two new developments in the EBV field. Adv. Cancer Res. 62: 79 (1993)

208. Kawanishi, M.: Topoisomerase l and II activities are required for Epstein-Barr virus replication. J. Gen. Virol 74: 2263 (1993)

209. Alford, C.A., Britt, W.J.: Cytomegalovirus. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p. 1981, Raven Press, New York, 1990

210. Stinski, M.F.: Cytomegalovirus and its replication. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., eds) Virology, vol. 2, p. 1959, Raven Press, New York, 1990

211. Sidweil, R.W., Arnett, G., Schabel, F.M.: in vitro effect of a variety of biologically active compounds on human cytomegalovirus. Chemotherapy 17: 259 (1972)

212. Bapat, A.R., Han, F., Liu, Z., Zhou, B., Cheng, Y.: Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells. J. Gen. Virol. 68: 2231 (1987)

213. Berns, K.l. (ed.): The Parvovirus. Plenum Publishing Corp., New York, 1983

214. Berns, K.l.: Parvoviridae and their replication, in: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B,, eds) Virology, vol. 2, p. 1743, Raven Press, New York, 1990

215. Gu, M.-L., Rhode, S.L.: Autonomous parvovirus DNA replication requires topoisomerase 1 and its activity is increased during infection. J. Virol. 65:1662 (1991)

216. Hizi, A., Gazi, A., Buthmann, D., Yaniv, A.: DNA-processing activities associated with the purified a, p2, ap2 molecular forms of avian sarcoma virus RNA-dependent DNA polymerase. J. Virol. 41: 974 (1982)

217. Weiss, R., Teich, N., Varmus, N., Coffin, J.: In: Molecular Biology of Tumor Viruses: RNA Tumor viruses. 2nd ed., Cold Spring Harbor, New York, 1985

218. Priel, E., Aflalo, E., Chechelnitsky, G., Benharroch, D.., Aboud, M. Segal, S.: Inhibition of retrovirus-induced disease in mice by camptothecin. J. Virol. 67: 3624 (1993)

219. Priel, E., Showalter, S.D., Roberts, M., Oroszlan, S., Segar, S„ Aboud, M., Blair, D.G.: Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J. 12: 4167 (1990)

220. McGuire, T.C., Crawford, T.B.: Immunology of a persistent retrovirus infectious anemia. Adv. Vet. Sci. Comp. Med. 23: 137 (1979)

221. McGuire, T.C., Henson, J.B., Quist, S.E.: Viral induced hemolysis in equine infectious anemia. Am. J. Vet Res. 30: 2091 (1969)

222. Kono, Y.K., Hirasawa, Y., Fukunaga, Y., Taniguchi, T.: Recrudesence of equine infectious anemia by treatment with immunosuppressive drugs. Natl. Inst. Anim. Health Q 16: 8 (1976)

223. McGuire, T.C., Crawford, T.B., Henson, J.B.: Immunofluorescent localization of equine infectious anemia virus in tissue. Am. J. Pathol. 62: 283 (1971)

224. Priel, E., Showalter, S.D., Roberts, M., Oroszlan, S., Blair, D.G.: The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells. J. Virol. 65: 4137 (1991)

225. Priel, E., Showalter, S.D., Blair, D.G.: inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytoxic doses of camptothecin, a topoisomerase I inhibitor, AIDS Res. Human Retrov. 7: 65 (1991)

226. Takahasi, N., Matsuda, M., Kojima, A., Sta, T, Andoh, T., Kurata, T., Nagashima, K., Hall, W.W.: Human immunodeficiency virus type 1 reverse transcriptase: Enhancement of activity by interaction with cellular topoisomerase I. Proc. Natl. Acad Sci. USA 92: 5694 (1995)

227. Wong-Staal, F.: Human immunodeficiency viruses and their replication. In: (Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M. S., Melnick, J.L., Monath, T.P., Roizman, B.. eds) Virology, vol. 2, p. 1529, Raven Press, New York, 1990

228. Li, C.J., Zhang, L.J., Dezube, B.J., Crumpacker, C.S., Pardee, A.B.: Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc. Natl. Acad Sci. USA 90: 1839 (1993)

229. Li, C.J., Wang, C., Pardee, A.B.: Camptothecin inhibits tat-mediated transactivation of type 1 human immunodeficiency virus. J. Biol. Chem. 269: 7051 (1994)

230. Pommier, Y., Podderin, B., Gupta, M., Jenkins, J.: DNA topoisomerases I and II cleavage sites in the type 1 human immunodeficiency virus (HIV-1). DNA promoter region. Biochem. Biophys. Res. Common. 200: 1601 (1991)

231. Berkhout, B., Silverman, R.H., Jeang, K.-T.: Tat transactivates the human immunodeficiency virus through a nascent RNA target. Cell 59: 273 (1989)

232. Haseltine W.A.: Molecular biology of the human immunodeficiency virus type 1. FASEB J. 5: 2349 (1991)

233. Steffy, K., Wong-Staal, F.: Genetic regulation of human immunodeficiency virus. Microbiol. Reviews 55: 193 (1991)

234. Huang, L.-M., Joshi, A., Willey, R., Oresntein, J., Jeang, K.-T.: Human immunodeficiency viruses regulated by alternative trans-activators: Genetic evidence for a novel non-transcriptionat function of Tat in virion infectivity. EMBO J. 13: 2886 (1994)

235. Chang, N.-K., Gailo, R.G., Ensoli, B.: Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J. Biomed Sci. 2: 189 (1995)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr